On-demand webinar: Success factors for commercializing rare disease and orphan drugs

By AmerisourceBergen

As new therapies for ultra-rare and rare disease emerge, what commercialization considerations are you overlooking?
Serving the unmet needs of patients facing the challenges of a rare disease requires a commercialization strategy that addresses all aspects of the product journey and the stakeholders identified within.  
 
Learn what those considerations are in this panel discussion featuring experts from AmerisourceBergen. You’ll learn what to address during pre-development and development, pre-launch, launch, and beyond – from experts who will cover everything from understanding the patient journey to payer strategy and why to work with a GPO.

Manufacturer Commercialization Strategy

AmerisourceBergen is the only pharmaceutical commercialization partner with the combination of proven solutions, diverse perspectives, and unmatched scale to make the most of scientific advances and change patient lives for the better. We build partnerships that unlock product potential and get medications to patients who need them.

Let's work together to envision new paths to healthier futures around the world.
Manufacturer commercialization Services